公开(公告)号：US08383357B2

公开(公告)日：2013-02-26

申请号：US11787044

申请日：2007-04-13

申请人： John D. Haley ,  Stuart Thomson ,  Filippo Petti

发明人： John D. Haley ,  Stuart Thomson ,  Filippo Petti

IPC分类号： G01N33/574

CPC分类号： G01N33/6893 ,  G01N33/5011 ,  G01N33/57407 ,  G01N33/57484 ,  G01N2800/52

摘要： The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with an EGFR kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an EGFR kinase inhibitor, comprising assessing whether the tumor cell has undergone an epithelial to mesenchymal transition (EMT), by determining the expression level of epithelial and/or mesenchymal biomarkers, wherein tumor cells that have undergone an EMT are substantially less sensitive to inhibition by EGFR kinase inhibitors. Improved methods for treating cancer patients with EGFR kinase inhibitors that incorporate the above methodology are also provided. Additionally, methods are provided for the identification of new biomarkers that are predictive of responsiveness of tumors to EGFR kinase inhibitors. Furthermore, methods for the identification of agents that restore the sensitivity of tumor cells that have undergone EMT to inhibition by EGFR kinase inhibitors are also provided.

摘要翻译： 本发明提供用于预测EGFR激酶抑制剂治疗癌症患者的有效性的诊断和预后方法。 提供了用于预测肿瘤细胞生长对EGFR激酶抑制剂抑制的敏感性的方法，包括通过测定上皮和/或间质生物标志物的表达水平来评估肿瘤细胞是否经历了上皮间质转化（EMT），其中 已经经历EMT的肿瘤细胞对EGFR激酶抑制剂的抑制基本上较不敏感。 还提供了用于治疗结合上述方法的EGFR激酶抑制剂的癌症患者的改进方法。 另外，提供了用于鉴定预测肿瘤对EGFR激酶抑制剂的反应性的新生物标志物的方法。 此外，还提供了用于鉴定恢复已经经历EMT的肿瘤细胞对EGFR激酶抑制剂抑制的敏感性的药剂的方法。

公开(公告)号：US20070212738A1

公开(公告)日：2007-09-13

申请号：US11787044

申请日：2007-04-13

申请人： John Haley ,  Stuart Thomson ,  Filippo Petti

发明人： John Haley ,  Stuart Thomson ,  Filippo Petti

IPC分类号： G01N33/574

CPC分类号： G01N33/6893 ,  G01N33/5011 ,  G01N33/57407 ,  G01N33/57484 ,  G01N2800/52

摘要： The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with an EGFR kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an EGFR kinase inhibitor, comprising assessing whether the tumor cell has undergone an epithelial to mesenchymal transition (EMT), by determining the expression level of epithelial and/or mesenchymal biomarkers, wherein tumor cells that have undergone an EMT are substantially less sensitive to inhibition by EGFR kinase inhibitors. Improved methods for treating cancer patients with EGFR kinase inhibitors that incorporate the above methodology are also provided. Additionally, methods are provided for the identification of new biomarkers that are predictive of responsiveness of tumors to EGFR kinase inhibitors. Furthermore, methods for the identification of agents that restore the sensitivity of tumor cells that have undergone EMT to inhibition by EGFR kinase inhibitors are also provided.

摘要翻译： 本发明提供用于预测EGFR激酶抑制剂治疗癌症患者的有效性的诊断和预后方法。 提供了用于预测肿瘤细胞生长对EGFR激酶抑制剂抑制的敏感性的方法，包括通过测定上皮和/或间质生物标志物的表达水平来评估肿瘤细胞是否经历了上皮与间质转化（EMT），其中 已经经历EMT的肿瘤细胞对EGFR激酶抑制剂的抑制基本上较不敏感。 还提供了用于治疗结合上述方法的EGFR激酶抑制剂的癌症患者的改进方法。 另外，提供了用于鉴定预测肿瘤对EGFR激酶抑制剂的反应性的新生物标志物的方法。 此外，还提供了用于鉴定恢复已经经历EMT的肿瘤细胞对EGFR激酶抑制剂抑制的敏感性的药剂的方法。